Search Results - "Schore, Reuven J."

Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932 by Schore, Reuven J., Angiolillo, Anne L., Kairalla, John A., Devidas, Meenakshi, Rabin, Karen R., Zweidler-McKay, Patrick, Borowitz, Michael J., Wood, Brent, Carroll, Andrew J., Heerema, Nyla A., Relling, Mary V., Hitzler, Johann, Kadan-Lottick, Nina S., Maloney, Kelly, Wang, Cindy, Carroll, William L., Winick, Naomi J., Raetz, Elizabeth A., Loh, Mignon L., Hunger, Stephen P.

Get full text

Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932 by Angiolillo, Anne L, Schore, Reuven J, Kairalla, John A, Devidas, Meenakshi, Rabin, Karen R, Zweidler-McKay, Patrick, Borowitz, Michael J, Wood, Brent, Carroll, Andrew J, Heerema, Nyla A, Relling, Mary V, Hitzler, Johann, Lane, Ashley R, Maloney, Kelly W, Wang, Cindy, Bassal, Mylène, Carroll, William L, Winick, Naomi J, Raetz, Elizabeth A, Loh, Mignon L, Hunger, Stephen P

“…AALL0932 evaluated two randomized maintenance interventions to optimize disease-free survival (DFS) while reducing the burden of therapy in children with newly…”
Get full text

The genomic landscape of juvenile myelomonocytic leukemia by Stieglitz, Elliot, Taylor-Weiner, Amaro N, Chang, Tiffany Y, Gelston, Laura C, Wang, Yong-Dong, Mazor, Tali, Esquivel, Emilio, Yu, Ariel, Seepo, Sara, Olsen, Scott R, Rosenberg, Mara, Archambeault, Sophie L, Abusin, Ghada, Beckman, Kyle, Brown, Patrick A, Briones, Michael, Carcamo, Benjamin, Cooper, Todd, Dahl, Gary V, Emanuel, Peter D, Fluchel, Mark N, Goyal, Rakesh K, Hayashi, Robert J, Hitzler, Johann, Hugge, Christopher, Liu, Y Lucy, Messinger, Yoav H, Mahoney, Donald H, Monteleone, Philip, Nemecek, Eneida R, Roehrs, Philip A, Schore, Reuven J, Stine, Kimo C, Takemoto, Clifford M, Toretsky, Jeffrey A, Costello, Joseph F, Olshen, Adam B, Stewart, Chip, Li, Yongjin, Ma, Jing, Gerbing, Robert B, Alonzo, Todd A, Getz, Gad, Gruber, Tanja A, Golub, Todd R, Stegmaier, Kimberly, Loh, Mignon L

“…Elliot Stieglitz, Mignon Loh and colleagues report the whole-exome sequencing of diagnostic and relapsed samples from patients with juvenile myelomonocytic…”
Get full text

Pediatric acute erythroid leukemias with monocytic antigen expression and novel chromosomal translocations by Zhu, Gord Guo, Inam, Zaina, Calleroz, Amanda, Pillai, Vinodh, Schore, Reuven J, Cheng, Jinjun

Get full text

Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia by Rodwin, Rozalyn L, Kairalla, John A, Hibbitts, Emily, Devidas, Meenakshi, Whitley, Moira K, Mohrmann, Caroline E, Schore, Reuven J, Raetz, Elizabeth, Winick, Naomi J, Hunger, Stephen P, Loh, Mignon L, Hockenberry, Marilyn J, Angiolillo, Anne L, Ness, Kirsten K, Kadan-Lottick, Nina S

“…Abstract Background Children with B-acute lymphoblastic leukemia (B-ALL) are at risk for chemotherapy-induced peripheral neuropathy (CIPN). Children’s Oncology…”
Get full text

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4 by Angiolillo, Anne L, Schore, Reuven J, Devidas, Meenakshi, Borowitz, Michael J, Carroll, Andrew J, Gastier-Foster, Julie M, Heerema, Nyla A, Keilani, Taha, Lane, Ashley R, Loh, Mignon L, Reaman, Gregory H, Adamson, Peter C, Wood, Brent, Wood, Charlotte, Zheng, Hao W, Raetz, Elizabeth A, Winick, Naomi J, Carroll, William L, Hunger, Stephen P

“…Asparaginase is a critical agent used to treat acute lymphoblastic leukemia (ALL). Pegaspargase (SS-PEG), a pegylated form of Escherichia coli L-asparaginase…”
Get full text

Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults by Dreyzin, Alexandra, Jacobsohn, David, Angiolillo, Anne, Wistinghausen, Birte, Schore, Reuven J., Perez, Evelio, Wells, Elizabeth, Terao, Joshua, Bonifant, Challice, Rohatgi, Radha, Dave, Hema, Vatsayan, Anant

Get full text

Longitudinal analysis of quality‐of‐life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial by Zheng, Daniel J., Lu, Xiaomin, Schore, Reuven J., Balsamo, Lyn, Devidas, Meenakshi, Winick, Naomi J., Raetz, Elizabeth A., Loh, Mignon L., Carroll, William L., Sung, Lillian, Hunger, Stephen P., Angiolillo, Anne L., Kadan‐Lottick, Nina S.

“…BACKGROUND Children with average‐risk acute lymphoblastic leukemia (AR‐ALL) face many challenges that can adversely affect their quality of life (QOL)…”
Get full text

Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4 by Schore, Reuven J., Devidas, Meenakshi, Bleyer, Archie, Reaman, Gregory H., Winick, Naomi, Loh, Mignon L., Raetz, Elizabeth A., Carroll, William L., Hunger, Stephen P., Angiolillo, Anne L.

“…The efficacy of asparaginase in acute lymphoblastic leukemia (ALL) is dependent on depletion of asparagine, an essential amino acid for ALL cells. The target…”
Get full text

Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group by Rabin, Karen R, Devidas, Meenakshi, Chen, Zhiguo, Ji, Lingyun, Kairalla, John, Hitzler, Johann K, Yang, Jun J, Carroll, Andrew J, Heerema, Nyla A, Borowitz, Michael J, Wood, Brent L, Roberts, Kathryn G, Mullighan, Charles G, Harvey, Richard C, Chen, I-Ming, Willman, Cheryl L, Reshmi, Shalini C, Gastier-Foster, Julie M, Bhojwani, Deepa, Rheingold, Susan R, Maloney, Kelly W, Mattano, Leonard A, Larsen, Eric C, Schore, Reuven J, Burke, Michael J, Salzer, Wanda L, Winick, Naomi J, Carroll, William L, Raetz, Elizabeth A, Loh, Mignon L, Hunger, Stephen P, Angiolillo, Anne L

“…Patients with Down syndrome (DS) and B-ALL experience increased rates of relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on…”
Get full text

Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932 by Schore, Reuven J., Angiolillo, Anne L., Kairalla, John A., Devidas, Meenakshi, Rabin, Karen R., Zweidler-McKay, Patrick, Borowitz, Michael J., Wood, Brent, Carroll, Andrew J., Heerema, Nyla A., Relling, Mary V., Hitzler, Johann, Kadan-Lottick, Nina S., Maloney, Kelly, Wang, Cindy, Carroll, William L., Winick, Naomi J., Raetz, Elizabeth A., Loh, Mignon L., Hunger, Stephen P.

Get full text

Surveillance imaging and early surgical intervention for improved CNS tumor outcomes in children with Li-Fraumeni syndrome: Children's National Hospital experience and literature review by Patel, Nirali, Felton, Kathleen, Bhattacharya, Surajit, Almira-Suarez, Maria Isabel, Eze, Augustine, Turner, Joyce, Keating, Robert, Oluigbo, Chima, Schore, Reuven J, Kilburn, Lindsay, Packer, Roger J, Myseros, John S, Bornhorst, Miriam

“…Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by germline mutations in the TP53 gene. CNS tumors are the fourth most common tumor type…”
Get full text

Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study by Oberley, Matthew J., Raikar, Sunil S., Wertheim, Gerald B., Malvar, Jemily, Sposto, Richard, Rabin, Karen R., Punia, Jyotinder N., Seif, Alix E., Cahen, Viviane C., Schore, Reuven J., Luca, Dragos C., Guinipero, Terri, Woods, William G., O’Gorman, Maurice R. G., Orgel, Etan

“…The rarity of mixed phenotype acute leukemia (MPAL) has precluded adequate data to incorporate minimal residual disease (MRD) monitoring into therapy. Fluidity…”
Get full text

Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemia by Rodwin, Rozalyn L, DelRocco, Natalie J, Hibbitts, Emily, Devidas, Meenakshi, Whitley, Moira K, Mohrmann, Caroline E, Schore, Reuven J, Raetz, Elizabeth, Winick, Naomi J, Hunger, Stephen P, Loh, Mignon L, Hockenberry, Marilyn J, Ma, Xiaomei, Angiolillo, Anne L, Ness, Kirsten K, Kairalla, John A, Kadan-Lottick, Nina S

“…Chemotherapy-induced peripheral neuropathy (CIPN), a common condition in children with acute lymphoblastic leukemia, can be challenging to diagnose. Using data…”
Get full text

Infectious Morbidity by Catheter Type in Neutropenic Children With Cancer by ORGEL, Etan, LINGYUN JI, PASTOR, William, SCHORE, Reuven J

“…Three central venous catheters types are commonly used in pediatric cancer: totally implantable catheters (ICs; eg, mediports, portacaths), tunneled…”
Get full text

Prognostic impact of minimal residual disease at the end of consolidation in NCI standard‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group by Rau, Rachel E., Dai, Yunfeng, Devidas, Meenakshi, Rabin, Karen R., Zweidler‐McKay, Patrick, Angiolillo, Anne, Schore, Reuven J., Burke, Michael J., Salzer, Wanda L., Heerema, Nyla A., Carroll, Andrew J., Winick, Naomi J., Hunger, Stephen P., Raetz, Elizabeth A., Loh, Mignon L., Wood, Brent L., Borowitz, Michael J.

“…The 5‐year disease‐free survival (DFS) of National Cancer Institute (NCI) high‐risk (HR) B‐lymphoblastic leukemia (B‐ALL) patients with end of induction (EOI)…”
Get full text

A Pediatric Case of Transformed Mycosis Fungoides in a BRCA2 Positive Patient by Gross, Andrea M, Turner, Joyce, Kirkorian, Anna Y, Okoye, Ginette A, Luca, Dragos C, Bornhorst, Miriam, Jacobs, Shana S, Williams, Kirsten M, Schore, Reuven J

“…Cutaneous T-cell lymphomas are very rare in children. Although mycosis fungoides is the most common of these rare cutaneous T-cell lymphomas in children,…”
Get full text

Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing by Huynh, Van, Laetsch, Theodore W., Schore, Reuven J., Gaynon, Paul, O'Brien, Maureen M.

“…Technologies for the detection of minimal residual disease (MRD) in leukemia and our understanding of the prognostic implications of MRD at different phases of…”
Get full text

Results from the Phase 1 Portion of a Trial of Oral Ixazomib Combined with Chemotherapy in Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoma in Children, Adolescents and Young Adults: A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium by Schafer, Eric S., Chi, Yueh-Yun, Malvar, Jemily, Rushing, Teresa, Doan, Andrew, Pacenta, Holly L., Schore, Reuven J., Sposto, Richard, Leong, Roy, Gaynon, Paul S., Rubnitz, Jeffrey E., Barredo, Julio C., Slone, Tamra, Pauly, Melinda, Wayne, Alan S., Bhojwani, Deepa, Horton, Terzah M.

“…Proteasome inhibitors potentiate anti-tumor effects of standard cytotoxic chemotherapy in childhood leukemia. Ixazomib is an oral proteasome inhibitor that has…”
Get full text

Real-World Performance of 2022 Revised World Health Organization (WHO) Criteria for Mixed Phenotype Acute Leukemia (MPAL) B/Myeloid Defined Only By Isolated MPO Expression (isoMPO) by Kovach, Alexandra E., Raikar, Sunil S., Malvar, Jemily, Oberley, Matthew J., Wertheim, Gerald, Rabin, Karen R., Punia, Jyotinder N., Seif, Alix, Schore, Reuven J., Luca, Dragos C., Guinipero, Terri L., Woods, William G., Cahen, Viviane, Chi, Yueh-Yun, O'Gorman, Maurice R.G., Wood, Brent L., Orgel, Etan

“…Mixed phenotype acute leukemia (MPAL) is biologically and immunophenotypically heterogeneous, and optimal diagnostic criteria remain unclear. The two current…”
Get full text